Antibodies

18 April 2016

Morphotek Announces Publication Of Phase 3 Results From MORAb-003-004 Trial In Platinum-Sensitive Ovarian Cancer Patients

18 April 2016

Mersana Therapeutics’ New Immunoconjugate Demonstrates Anti-Cancer Activity in Non-Small Cell Lung Cancer and Ovarian Cancer Tumor Models

18 April 2016

Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL)

18 April 2016

Immunomedics Announces Potent Anti-Tumor Activities with IMMU-114 in Preclinical Study in Acute and Chronic Leukemia

18 April 2016

ImmunoGen Announces Initiation of Clinical Testing of First-in-Class IMGN779 for Acute Myeloid Leukemia

18 April 2016

MorphoSys Licensing Partner GSK Starts Phase 2 Study with GSK3196165 (MOR103) in Hand Osteoarthritis

18 April 2016

Innate Pharma presents new CD73 checkpoint inhibitor program

18 April 2016

Jounce Therapeutics Presents Data Highlighting Advances From Two Programs in its Immuno-Oncology Pipeline at the 2016 AACR Annual Meeting

18 April 2016

Precision Biologics, a NantWorks Company, to Present Combination Immunotherapy of a Novel Neo-Epitope Antibody Targeting Ovarian and Uterine Cancer at the AACR Annual Meeting 2016

18 April 2016

First Presentation of Two-Year Overall Survival Data for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) Showed Superior Efficacy Versus Yervoy Alone in Advanced Melanoma

14 April 2016

U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Supplemental Biologics License Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients

13 April 2016

Bio Products Laboratory, Ltd Announces FDA Submission of Biologics License Supplement for Gammaplex 10%

13 April 2016

FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Recurrent or Metastatic Head and Neck Cancer, and Grants Priority Review

12 April 2016

Symphogen Initiates Anti-MET Clinical Program and Presents Pre-Clinical Anti-MET Data at Annual AACR Meeting April 18th in New Orleans

12 April 2016

ADC Therapeutics Doses First Patient in a Phase I Clinical Trial of ADCT-402 for Patients with B-cell lineage Acute Lymphoblastic Leukemia

11 April 2016

FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer

8 April 2016

Ludwig Cancer Research and CRI initiate clinical trial of immunotherapy for ovarian cancer

7 April 2016

MorphoSys and Galapagos Initiate Phase 1 Study in Joint Antibody Program MOR106

6 April 2016

REMD Biotherapeutics Announces Dosing of First Type 1 Diabetes Patient with REMD-477, a Glucagon Receptor Monoclonal Antibody

6 April 2016

European Commission Approves Expanded Use of Opdivo® (nivolumab) to Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

6 April 2016

European Commission Approves Bristol-Myers Squibb’s Opdivo® (nivolumab) for Previously Treated Advanced Renal Cell Carcinoma

6 April 2016

MorphoSys Initiates Phase 2 Combination Trial of MOR208 and Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

6 April 2016

FDA Approves INFLECTRA™ (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications

5 April 2016

Merck and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma

4 April 2016

AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients, from Six Years of Age, with Moderately to Severely Active Crohn’s Disease

4 April 2016

XOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO Meeting

4 April 2016

Alder Presents Preclinical Data for ALD1613 at ENDO 2016

4 April 2016

Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations

2 April 2016

Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide

2 April 2016

Pfizer Announces Positive Topline Results from Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

GPC3-Targeted Immunotherapy Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

TROP-2-Targeted Immunotherapy Pipeline Review

Ustekinumab (Stelara) Biosimilars Pipeline Review

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Report Package: Claudin 18.2-Targeted Immunotherapeutics